Search research articles
Contact Us
Filters
Showing results (71-80 of 150) with videos related to
Page
of 15
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 11, 2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation
Ajay K Nooka, Heather R Johnson, Jonathan L Kaufman, et al.
Cancer
|
July 27, 2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
Yehuda Z Patt, Manal M Hassan, Alvaro Aguayo, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Blood Advances
|
February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
Sayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
Cindy Varga, Myra Robinson, Vikas Gupta, et al.
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood Cancer Journal
|
October 21, 2024
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
Niels W C J van de Donk, Nizar Bahlis, Luciano J Costa, et al.
American Journal of Cancer Research
|
July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma
Robert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Journal of Comparative Effectiveness Research
|
April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Amrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Blood
|
April 5, 2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
Harold C Sullivan, Christian Gerner-Smidt, Ajay K Nooka, et al.
Page
of 15
Search research articles
Search
Showing results (71-80 of 150) with videos related to
Sort By:
Page
of 15
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 11, 2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation
Ajay K Nooka, Heather R Johnson, Jonathan L Kaufman, et al.
Cancer
|
July 27, 2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
Yehuda Z Patt, Manal M Hassan, Alvaro Aguayo, et al.
Cancer
|
November 6, 2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
Ajai Chari, Sagar Lonial, Tomer M Mark, et al.
Blood Advances
|
February 6, 2025
Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma
Sayalee V Potdar, Shivani Kapadia, Maryam I Azeem, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 8, 2025
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes
Cindy Varga, Myra Robinson, Vikas Gupta, et al.
American Journal of Hematology
|
April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
Ajai Chari, Caitlin Costello, Amrita Krishnan, et al.
Blood Cancer Journal
|
October 21, 2024
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
Niels W C J van de Donk, Nizar Bahlis, Luciano J Costa, et al.
American Journal of Cancer Research
|
July 12, 2021
A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma
Robert F Cornell, Michael R Bishop, Shaji Kumar, et al.
Journal of Comparative Effectiveness Research
|
April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
Amrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Blood
|
April 5, 2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
Harold C Sullivan, Christian Gerner-Smidt, Ajay K Nooka, et al.
Page
of 15